“Patient Preference for Calcipotriene 0.005% Betamethasone Dipropionate 0.064% Foam or Topical Suspension Vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study”. 2018. SKIN The Journal of Cutaneous Medicine 2 (S1): S10. https://doi.org/10.25251/skin.2.supp.10.